PEGAVISION CORPORATION – Trademark Portfolio
Entity Type: 03
PEGAVISION CORPORATION holds 18 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 16 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 12 trademarks are registered. Notable registered marks include NUVIVE, AQUAMAX, BIOAQUA, PURAVIEW, and PEGAVISION. The owner is based in Taoyuan City.
2F.-1, No. 5, Xingye St., Shanding Vil.
Guishan Dist.
Taoyuan City 33341 , TW
Showing of trademarks Trademarks
Trademark Classifications
PEGAVISION CORPORATION's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does PEGAVISION CORPORATION have?
PEGAVISION CORPORATION has 18 U.S. trademarks filed with the USPTO. Of these, 12 registered, 1 abandoned, 5 cancelled.
What trademark classes does PEGAVISION CORPORATION file in?
PEGAVISION CORPORATION files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are PEGAVISION CORPORATION's most well-known trademarks?
PEGAVISION CORPORATION's registered trademark portfolio includes well-known marks such as NUVIVE, AQUAMAX, BIOAQUA, PURAVIEW, and PEGAVISION. These are among 12 currently registered trademarks in the portfolio.
What is PEGAVISION CORPORATION's trademark registration success rate?
PEGAVISION CORPORATION has a 67% trademark registration rate, with 12 out of 18 resolved applications resulting in successful registration. Currently, 0 applications are pending review.